research P133 Anifrolumab treatment improves quality of life and decreases corticosteroid use in patients with SLE
Anifrolumab improves quality of life and reduces steroid use in SLE patients.
Search
for
Sort by
Research
720-750 / 1000+ results 
research FDA declines approval of testosterone drug for third time
The FDA rejected a testosterone drug again due to safety concerns.
research Sustained Scalp, Eyebrow, and Eyelash Hair Regrowth with Ritlecitinib Through Week 48 in Patients with Alopecia Areata: Post-Hoc Analysis of the ALLEGRO Phase 2b/3 Study
Ritlecitinib effectively maintains hair regrowth in alopecia areata patients.
research Treatment of alopecia areata with JAK inhibitors: a review of the literature
JAK inhibitors can help regrow hair in alopecia areata but have potential long-term risks and require careful monitoring.
research Patient Profile and Treatment Characteristics of Early Ritlecitinib Initiators in the US
Ritlecitinib provides new treatment options for diverse alopecia areata patients.
research Refractory folliculitis decalvans treated with adalimumab: A case series of 23 patients
Adalimumab improved folliculitis decalvans in most patients.
research A Cost-per-Responder Analysis of Ritlecitinib vs Baricitinib in Severe Alopecia Areata
Ritlecitinib is more effective and cheaper than baricitinib for treating severe alopecia areata.
research 42146 Concurrent improvement in scalp hair and eyebrow or eyelash regrowth in patients with severe alopecia areata treated with baricitinib
Baricitinib treatment can help regrow scalp hair and eyebrows or eyelashes in people with severe alopecia areata.
research Efficacy of Ritlecitinib in Patients with Alopecia Areata by Extent of Hair Loss: Results from the Phase 2b/3 and Phase 3 ALLEGRO Clinical Trials
Ritlecitinib effectively promotes hair regrowth in severe and very severe alopecia areata.
research Bimatoprost
research Baricitinib Withdrawal and Retreatment in Patients With Severe Alopecia Areata
Continuous baricitinib is needed to keep hair regrowth in severe alopecia areata.
research Clinical and Dermoscopic Evaluation of the Safety and Efficacy of Oral baricitinib (JAK Inhibitor) in Treatment of Localized Vitiligo Either Alone or with Topical Tacrolimus
Baricitinib is effective and safe for treating localized vitiligo, alone or with topical tacrolimus.
research P123 : Oral Janus kinase inhibitors for the treatment of alopecia areata: a systematic review and metaanalysis
Both tofacitinib and ruxolitinib are effective and tolerable for treating alopecia areata.
research Real‐life effectiveness and safety of baricitinib in adults with alopecia areata: A multicentre study
Baricitinib effectively reduces hair loss in alopecia areata and is well-tolerated.
research New-onset systemic lupus erythematosus beginning as class V lupus nephritis after COVID-19 vaccination
COVID-19 vaccination may trigger lupus in some people.
research Patient satisfaction with hair regrowth in a study of ritlecitinib: a plain language summary
Patients were very satisfied with hair regrowth after taking ritlecitinib for alopecia areata.
research Treatment of alopecia universalis with topical Janus kinase inhibitors – a double blind, placebo, and active controlled pilot study
Topical JAK inhibitors may help treat alopecia universalis by promoting hair regrowth.
research Graham Little-Lassueur Syndrome with Hypertrophic Lichen Planus in a Patient with Chronic Hepatitis C
A woman with chronic hepatitis C had a rare skin condition linked to her illness.
research Polyglandular Autoimmune Syndrome Type 3D : A Case Report
Autoimmune Polyendocrine Syndromes involve specific combinations of endocrine and non-endocrine autoimmune diseases.
research P64 Efficacy of baricitinib in patients with different degrees of severe alopecia areata: 52-week results from BRAVE-AA1 and BRAVE-AA2
Baricitinib was effective in treating severe and very severe alopecia areata after 52 weeks.
research Patient-Reported Satisfaction with Hair Regrowth in a Study of Ritlecitinib in Alopecia Areata: Results from ALLEGRO-2b/3
Ritlecitinib improves hair regrowth satisfaction in alopecia areata patients.
research 277 An open label pilot clinical trial of the JAK inhibitor tofacitinib for alopecia areata
Tofacitinib, a JAK inhibitor, improved hair regrowth in most patients with severe alopecia areata and had minimal side effects.
research Lenalidomide for refractory cutaneous manifestations of pediatric systemic lupus erythematosus
Lenalidomide effectively and safely treats skin symptoms in pediatric lupus, reducing the need for prednisone.
research [Lupus cystitis and peritonitis successfully treated with intravenous cyclophosphamide pulse therapy: a case report].
Intravenous cyclophosphamide effectively treated steroid-resistant lupus cystitis and peritonitis.
research SnapshotDx Quiz: March 2016
JAK inhibitors may help treat alopecia areata by reversing hair loss.
research Alopecia Universalis: an extremely rare but probable adverse effect of adalimumab
Adalimumab can cause complete hair loss in rare cases.
research 0433 JAK inhibitor halts the progression of acute exacerbation of alopecia areata
Baricitinib stops hair loss and promotes regrowth in alopecia areata.
research Effective use of ustekinumab in a patient with concomitant psoriasis, vitiligo, and alopecia areata
Ustekinumab significantly improved psoriasis, vitiligo, and alopecia areata in a patient.
research Acquired trichomegaly with topiramate
A woman's eyelashes grew thicker and longer after taking topiramate, but returned to normal when she stopped the medication.
research Efficacy and safety of ritlecitinib, an oral JAK3 /TEC family kinase inhibitor, in adolescent and adult patients with alopecia totalis and alopecia universalis
Ritlecitinib helps regrow hair in people with alopecia totalis and universalis and is safe to use.